Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Neoplasm Metastasis 2 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1 Hemangiosarcoma 1 HER2-positive Breast Cancer 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Endometrial Neoplasms 1 Disease Progression 1 Colonic Neoplasms 1 Carcinoma, Lobular 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 23 Cisplatin 22 durvalumab 13 pembrolizumab 8 Oxaliplatin 7 Capecitabine 7 Fluorouracil 6 Leucovorin 5 Bevacizumab 5 lenvatinib 4 Albumin-Bound Paclitaxel 4 130-nm albumin-bound paclitaxel 4 Nivolumab 3 Liquid Biopsy 3 Injections 3 Folfox protocol 3 zanidatamab 2 trifluridine tipiracil drug combination 2 tremelimumab 2 tislelizumab 2 ivosidenib 2 futibatinib 2 apatinib 2 Trastuzumab 2 Taxes 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Drug Therapy 2 Carboplatin 2 Blood Specimen Collection 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Biliary Tract Neoplasms × neratinib × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡